On April 30, Bristol-Myers Squibb announced that the world's first myocardial myosin inhibitor, mefantal (generic name: mavacitai capsules) has received priority review approval from the China National Drug Administration for the treatment of adult patients with obstructive hypertrophic cardiomyopathy (HCM) with grade II-III cardiac function by the New York Heart Association (NYHA) to improve exercise capacity and symptoms.
百时美施贵宝：心肌肌球蛋白抑制剂迈凡妥在中国获批，用于治疗梗阻性肥厚型心肌病成人患者
Bristol-Myers Squibb: Myocardial Myosin Inhibitor Meifantol Approved in China to Treat Adult Patients with Obstructive Hypertrophic Cardiomyopathy
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.